QurAlis chief scientific officer Dan Elbaum (center) works with researchers in the ALS biotech’s Cambridge, MA lab.
ALS biotech QurAlis gets $88M boost from four pharmas for pair of PhI studies
QurAlis picked up $88 million for two Phase I studies, hoping to ride regulatory waves driven by the recent FDA approval of Amylyx Pharmaceuticals’ ALS therapy.
Four biopharmas — Eli Lilly, Amgen, Sanofi and Mitsubishi Tanabe’s VC arm — are bankrolling a Series B for the biotech from Harvard stem cell pioneers Kevin Eggan and Clifford Woolf. In December, the startup began in-human trials of two therapeutics for patients with certain types of the progressive muscle weakness disease, which comes with a short life expectancy.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
